Log In
Print
BCIQ
Print
Print this Print this
 

STX-100

  Manage Alerts
Collapse Summary General Information
Company Biogen Inc.
DescriptionHumanized mAb against integrin alpha(V)beta(6)
Molecular Target Integrin alpha(V)beta(6)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationPulmonary fibrosis
Indication DetailsTreat idiopathic pulmonary fibrosis (IPF)
Regulatory Designation U.S. - Orphan Drug (Treat idiopathic pulmonary fibrosis (IPF))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$562.5M

$75.0M

$487.5M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today